Analyzing Atrion (NASDAQ:ATRI) and Sensus Healthcare (NASDAQ:SRTS)
Atrion (NASDAQ:ATRI) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
Risk & Volatility
Atrion has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500.
This table compares Atrion and Sensus Healthcare’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Atrion and Sensus Healthcare’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Atrion||$152.45 million||9.55||$34.26 million||N/A||N/A|
|Sensus Healthcare||$26.43 million||3.94||-$2.02 million||($0.14)||-45.14|
Atrion has higher revenue and earnings than Sensus Healthcare.
Insider and Institutional Ownership
64.7% of Atrion shares are owned by institutional investors. Comparatively, 9.8% of Sensus Healthcare shares are owned by institutional investors. 22.1% of Atrion shares are owned by company insiders. Comparatively, 31.2% of Sensus Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Atrion pays an annual dividend of $5.40 per share and has a dividend yield of 0.7%. Sensus Healthcare does not pay a dividend. Atrion has raised its dividend for 16 consecutive years.
This is a summary of current recommendations and price targets for Atrion and Sensus Healthcare, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sensus Healthcare has a consensus target price of $9.50, suggesting a potential upside of 50.32%. Given Sensus Healthcare’s higher possible upside, analysts plainly believe Sensus Healthcare is more favorable than Atrion.
Atrion beats Sensus Healthcare on 11 of the 14 factors compared between the two stocks.
Atrion Company Profile
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 Myocardial Protection System that delivers fluids and medications, mixes critical drugs, and controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary robotic intraoperative radiation therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.